Relationship between prostate cancer mortality and number of unfavourable risk factors in men treated with definitive brachytherapy

BJU International

Volumn 106, Issue 6, 2010, Pages 809-814

  Taira, Al V ^a   Merrick, Gregory S ^c   Galbreath, Robert W ^c   Butler, Wayne M ^c   Lief, Jonathan H ^c   Wallner, Kent E ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WHEELING JESUIT UNIVERSITY   (United States)

Author keywords

brachytherapy; percentage positive biopsies; prostate cancer mortality; PSA velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ANTIGEN SPECIFICITY; ARTICLE; BRACHYTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; DIABETES MELLITUS; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RISK FACTOR; SMOKING; TUMOR BIOPSY; AGED; COHORT ANALYSIS; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE; TREATMENT OUTCOME;

AGED; BRACHYTHERAPY; COHORT STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RISK FACTORS; TREATMENT OUTCOME;

EID: 77956211260     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09269.x     Document Type: Article

References (28)

1. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome afterradical prostatectomy, external beamradiation therapy, or interstitial radiationtherapy for clinically localized prostatecancer. JAMA 1998; 280: 969-74
2. Pisansky TM, Kahn MJ, Bostwick DG. Anenhanced prognostic system for clinicallylocalized carcinoma of the prostate. Cancer 1997; 79: 2154-61
3. D'Amico AV, Cote K, Loffredo M et al. Determinants of prostate cancer-specificsurvival after radiation therapy forpatients with clinically localized prostatecancer. J Clin Oncol 2002; 20: 4567-73
4. Bittner N, Merrick GS, Galbreath RW et al. Primary causes of death afterpermanent prostate brachytherapy. Int JRadiat Oncol Biol Phys 2008; 72: 433-40
5. Kupelian PA, Elshaikh M, Reddy CA et al. Comparison of the efficacy of localtherapies for localized prostate cancer inthe prostate-specific antigen era: a largesingle-institution experience with radicalprostatectomy and external-beamradiotherapy. J Clin Oncol 2002; 20: 3376-85
6. Sylvester JE, Grimm PD, Blasko JC et al. 15-Year biochemical relapse free survivalin clinical Stage T1-T3 prostate cancerfollowing combined external beamradiotherapy and brachytherapy; Seattleexperience. Int J Radiat Oncol Biol Phys 2007; 67: 57-64
7. Kupelian PA, Willoughby TR, Reddy CA et al. Hypofractionated intensitymodulatedradiotherapy (70 Gy at2.5 Gyper fraction) for localized prostate cancer:Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007; 68: 1424-30
8. Zelefsky MJ, Yamada Y, Hunt M et al . Comparison of 7-year outcomes between LDR brachytherapy and high dose IMRT for patients with clinically localizedprostate cancer. Int J Radiat Oncol BiolPhys 2007; 69: S178
9. D'Amico AV, Chen MH, Roehl KA et al. Preoperative PSA velocity and the risk ofdeath from prostate cancer after radicalprostatectomy. N Engl J Med 2004; 351:125-35
10. D'Amico AV, Renshaw AA, Sussman B et al. Pretreatment PSA velocity and risk ofdeath from prostate cancer followingexternal beam radiation therapy. JAMA 2005; 294: 440-7
11. D'Amico AV, Chen MH, Catalona WJ et al. Prostate cancer-specific mortalityafter radical prostatectomy or externalbeam radiation therapy in men with1 ormore high-risk factors. Cancer 2007; 110: 56-61
12. Tsai HK, Chen MH, McLeod DG et al. Cancer-specific mortality after radiationtherapy with short-course hormonaltherapy or radical prostatectomy in menwith localized, intermediate-risk to highriskprostate cancer. Cancer 2006; 107: 2597-603
13. Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three-dimensionalconformal radiation therapy affects theoutcome in prostate cancer. Int J RadiatOncol Biol Phys 1998; 41: 491-500
14. Patel DA, Presti JC, McNeal JE et al. Preoperative PSA velocity is anindependent prognostic factor for relapseafter radical prostatectomy. J Clin Oncol 2005; 23: 6157-62
15. Nguyen PL, Chen MH, Catalona WJ et al. Predicting prostate cancer mortalityamong men with intermediate to highriskdisease and multiple unfavorable riskfactors. Int J Radiat Oncol Biol Phys 2009; 73: 659-64
16. Partin AW, Mangold LA, Lamm DM et al. Contemporary update of prostatecancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843-8
17. Merrick GS, Butler WM. Modifieduniform seed loading for prostatebrachytherapy: rationale, design, andevaluation. Tech Urol 2000; 6: 78-84
18. Merrick GS, Butler WM, Wallner KE et al. Dosimetry of an extracapsularanulus following permanent prostatebrachytherapy. Am J Clin Oncol 2007; 30: 228-33
19. Bolla M, Collette L, van Tienhoven G et al. Ten year results of long termadjuvant androgen deprivation withgoserlin in patients with locally advancedprostate cancer treated withradiotherapy: a phase III EORTC study. IntJ Radiat Oncol Biol Phys 2008; 72: s30
20. D'Amico AV, Chen MH, Renshaw AA et al. Androgen suppression and radiationvs radiation alone for prostate cancer: arandomized trial. JAMA 2008; 299: 289-95
21. Roach M III, Bae K, Speight J et al. Short-term neoadjuvant androgendeprivation therapy and external-beamradiotherapy for locally advancedprostate cancer: long-term results ofRTOG 8610. J Clin Oncol 2008; 26: 585-91
22. Stock RG, Ho A, Cesaretti JA et al. Changing the patterns of failure forhigh-risk prostate cancer patients byoptimizing local control. Int J Radiat OncolBiol Phys 2006; 66: 389-94
23. Stone NN, Potters L, Davis BJ et al. Multicenter analysis of effect of highbiologic effective dose on biochemicalfailure and survival outcomes in patientswith Gleason score7-10 prostate cancertreated with permanent prostatebrachytherapy. Int J Radiat Oncol BiolPhys 2009; 73: 341-6
24. Merrick GS, Butler WM, Wallner KE et al. Androgen deprivation therapy doesnot impact cause-specific or overall survival in high-risk prostate cancermanaged with brachytherapy andsupplemental external beam. Int J RadiatOncol Biol Phys 2007; 68: 34-40
25. Jemal A, Siegel R, Ward E et al. Cancerstatistics, 2009. CA Cancer J Clin 2009; 59:225-49
26. Rosenthal SA, Bae K, Pienta KJ et al. Phase III multi-institutional trial ofadjuvant chemotherapy with paclitaxel,estramustine, and oral etoposidecombined with long-term androgensuppression therapy and radiotherapyversus long-term androgen suppressionplus radiotherapy alone for high-riskprostate cancer: preliminary toxicityanalysis of RTOG 99-02. Int J Radiat OncolBiol Phys 2009; 73: 672-8
27. O'Brien FM, Cronin AM, Smith B et al. Pretreatment prostate-specific antigenvelocity and doubling time are associatedwith outcome but neither improvesprediction of outcome beyondpretreatment PSA alone in patientstreated with radical prostatectomy. J ClinOncol 2009; 27: 3591-7
28. Fitzpatrick JM, Banu E, Oudard S. Prostate-specific antigen kinetics inlocalized and advanced prostate cancer. BJU Int 2009; 103: 578-87